Navigation Links
SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
Date:5/28/2009

eared from the body.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain FDA and other required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the company's Annual Report on Form 10-KSB for the year ended December 31, 2008 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
2. SyntheMed Announces FDA Clearance of SinusShield(TM)
3. SyntheMed Announces New Management Appointments
4. SyntheMed Completes $4.0 Million Equity Placement
5. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
6. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
7. SyntheMed Files Universal Shelf Registration
8. SyntheMed to Present at the Acumen BioFin Conference
9. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
10. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
11. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed ... developer, and marketer of over-the-counter (OTC) medicinal and ... research opinion on the company based on low ... , Non-Prescription, All Natural Product to Treat ... Product Outperforms #1 Prescription Competitor , Currently ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... 25, 2012 Aviir Diagnostic Laboratory announced today ... with MultiPlan, Inc. for ancillary diagnostics laboratory testing. ... PHCS and PHCS Savility Networks. Aviir ... from the Stanford University School of Medicine to ...
... The rise of the corporate venture fund and the ... themes at BioTrinity, the-premier European biopartnering and investment conference ... comprehensive support for bioscience businesses in the Oxford and ... day of the conference saw senior figures from Merck ...
... well-respected, independent, third-party laboratory has tested for Tuberculosis (TB) ... (BioNanoPore) test kits and achieved the detection of ... culture times for conventional technologies take a minimum of ... concurrent tests for TB at the same facility, using ...
Cached Biology Technology:Aviir Laboratories Announce National Agreement With MultiPlan 2Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity 2Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity 3NanoLogix Provides Testing and Operations Update 2NanoLogix Provides Testing and Operations Update 3
(Date:5/23/2013)... Neuron , the team reveal the interplay of brain ... by the Wellcome Trust and BBSRC. , By ... improve our perceptual abilities. While these changes can affect ... affect the fidelity of that response. , ... "When you communicate with others, you can make yourself ...
(Date:5/22/2013)... that can detect molecular variants in chemical mixtures ... most important, though time-consuming, processes in analytical chemistry. ... , post-doctoral researcher David Patterson, Professor of Physics John ... Free-Electron Laser Science (CFEL) in Hamburg, Germany developed a ... molecular variants apart, and to determine how much variant ...
(Date:5/22/2013)... in cellular DNA can endanger the whole organism, as ... at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how byproducts ... helix. , The DNA in our cells controls the ... bodies. The instructions for this are encoded in the ... the bases adenine (A), cytosine (C), guanine (G) and ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3DNA damage: The dark side of respiration 2
... PHILADELPHIA A new study by University of Pennsylvania ... humans, that ventilators combined with diaphragm disuse contributes to ... eighteen hours. Muscle atrophy in the diaphragm is a ... mechanical ventilation often have difficulty breathing after being removed ...
... German . , The "Large Molecule Heimat" ... forming region Sagittarius B2. In this source of only 0,3 ... formed star, most of the interstellar molecules known to date ... ethyl alcohol, formaldehyde, formic acid, acetic acid, glycol aldehyde (a ...
... Humans have regularly been introducing exotic species into ... nutritional necessities or meet less indispensable purposes such ... environments are not always adapted for hosting new ... wild rabbit into Australia or brown fario trout ...
Cached Biology News:Long-term use of mechanical ventilation contributes to the deterioration of human diaphragm muscle 2New organic molecule in space 2Conservation of freshwater fish biodiversity: a challenge for the countries of the South 2Conservation of freshwater fish biodiversity: a challenge for the countries of the South 3
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
Recombinant Equine IL-4, CF...
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: